Inquiry Basket
Loading ......
Filter By Product Search for
Norfluoxetine
Norfluoxetine Full Name
Norfluoxetine
Norfluoxetine Introduction
Norfluoxetine is the major active metabolite of fluoxetine and contributes substantially to the long-lasting pharmacological effects observed during antidepressant therapy. Because norfluoxetine has a longer elimination half-life than its parent compound and accumulates during chronic treatment, its biological activity is highly relevant when evaluating therapeutic efficacy, adverse reactions, and drug-drug interactions. While both fluoxetine and norfluoxetine primarily influence serotonergic neurotransmission through inhibition of the serotonin transporter (SERT, encoded by SLC6A4), increasing evidence indicates that norfluoxetine possesses distinct pharmacological properties beyond serotonin reuptake inhibition. It interacts with multiple ion channels, including two-pore domain potassium (K2P) channels and voltage-gated potassium channels, making it an important molecule for researchers investigating depression, neurophysiology, pharmacogenomics, and precision medicine. Understanding norfluoxetine is particularly valuable for clinicians and scientists seeking to explain delayed treatment responses, prolonged drug exposure, or unexpected neurological effects during selective serotonin reuptake inhibitor (SSRI) therapy.
The biological activity of norfluoxetine extends well beyond its role as an SSRI metabolite. Pharmacogenomic studies have demonstrated that CYP2D6 is the principal determinant of fluoxetine-to-norfluoxetine conversion under routine clinical conditions, whereas common variants in CYP2C9 and CYP2C19 contribute comparatively little to interindividual variability. Patients with reduced CYP2D6 activity exhibit significantly altered fluoxetine/norfluoxetine metabolic ratios, highlighting the importance of CYP2D6-guided dosing strategies for optimizing treatment outcomes and minimizing adverse effects. In addition to its pharmacokinetic relevance, norfluoxetine has emerged as a valuable pharmacological tool for studying neuronal ion channels. Experimental studies have shown that it selectively inhibits TREK-1 (KCNK2) and TREK-2 (KCNK10) leak potassium channels, allowing researchers to distinguish TREK-dependent potassium currents in electrophysiological experiments. More recently, norfluoxetine has also been identified as a potent inhibitor of the Kv3.2 potassium channel (KCNC2), displaying greater inhibitory potency than fluoxetine and preferentially suppressing gain-of-function disease-associated variants. These findings suggest that norfluoxetine may exert therapeutic effects through mechanisms independent of serotonin transport inhibition, expanding its significance in neuropharmacology and ion channel research.
Growing evidence links norfluoxetine-associated targets to several neurological and psychiatric disorders, broadening its potential clinical importance. Beyond its established contribution to the treatment of major depressive disorder and anxiety disorders through serotonergic modulation, selective inhibition of pathogenic KCNC2 variants has demonstrated encouraging therapeutic potential in developmental and epileptic encephalopathy (DEE). Clinical observations have shown that fluoxetine therapy, likely supported by therapeutically relevant brain concentrations of norfluoxetine, can improve seizure control and behavioral outcomes in patients carrying gain-of-function KCNC2 mutations, highlighting a promising precision medicine strategy for rare genetic epilepsies. Meanwhile, studies involving TREK-1 have strengthened its role as an experimental target for understanding neuronal excitability, anesthetic mechanisms, pain processing, and mood regulation, although compensatory ion channel pathways may influence physiological responses in vivo. Beyond human health, norfluoxetine has also attracted attention as a persistent environmental contaminant capable of altering endocrine-related gene expression in aquatic organisms, reinforcing its broader biological significance. Collectively, these discoveries position norfluoxetine not merely as an active metabolite of fluoxetine, but as a biologically important molecule whose interactions with SLC6A4, KCNC2, TREK-1, TREK-2, and CYP2D6 continue to provide valuable insights into antidepressant pharmacology, neurological disease mechanisms, personalized medicine, and translational drug discovery.
Alternate Names for Norfluoxetine
Norfluoxetine
Loading ......
